On the afternoon of March 16, the Hong Kong Stock Connect innovative drug sector experienced another surge, with the 100% innovative drug R&D-focused HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION TRADING OPEN ENDED INDEX SECURITIES INVES (520880) showing active performance. Its intraday price rose by 2.53%, with a trading volume of 377 million yuan.
Among the constituent stocks, Changfeng Pharmaceutical led the gains with an increase of 31.83%, followed by BioMap-B and Akeso Biopharma, which rose by 5.9% and 5.72%, respectively. On the other hand, Zhonghui Biotech-B performed weakly, declining by 17.84%, while Baoji Pharmaceutical-B and Jingfang Pharmaceutical-B fell by 5.35% and 5.03%, respectively.
In terms of news, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, tracked by HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION TRADING OPEN ENDED INDEX SECURITIES INVES (520880), completed an adjustment of its constituent stocks on March 9, adding 13 new companies. These additions cover cutting-edge fields such as AI-driven drug development and gene editing, bringing the total number of index constituents to 50. Additionally, this year's government work report explicitly positioned biopharmaceuticals as an "emerging pillar industry," marking a new strategic development phase for the sector.
Shanghai Securities pointed out that recent business development transactions for Chinese innovative drugs have been active, with notable amounts and a shift toward earlier R&D stages. The cost and efficiency advantages of these drugs continue to gain global recognition. Several heavyweight collaborations involving pre-clinical assets highlight the global acknowledgment of China's capabilities in original innovation.
Debon Securities noted that innovative drugs have been mentioned in the government work report for three consecutive years. The 2026 report elevated the biomedical industry from an emerging sector to a pillar industry and reinforced comprehensive policy support across the entire value chain. Domestic innovative drugs are receiving increased policy attention, with the industry achieving continuous breakthroughs. The number of approved Class 1 innovative drugs has been steadily growing. Since 2025, overseas business development for domestic innovative drugs has accelerated significantly. In January 2026 alone, the potential total value of Chinese innovative drug BD transactions reached approximately $34.6 billion, a year-on-year increase of about 55%.
HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION TRADING OPEN ENDED INDEX SECURITIES INVES (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index. The top ten weighted stocks in the index are CSPC Pharmaceutical Group, BeiGene, Innovent Biologics, Akeso Biopharma, Sino Biopharmaceutical, Hansoh Pharmaceutical, 3SBio, Kelun-BTB Biotechnology-B, China Medical System, and Zai Lab.
Data sources include the Shanghai and Shenzhen stock exchanges and publicly available information.
Risk warning: The above product is issued and managed by the fund management company. Selling agencies do not assume responsibility for the investment, redemption, or risk management of the product. Investors should carefully read the "Fund Contract," "Prospectus," "Fund Product Summary," and other legal fund documents to understand the risk-return characteristics of the fund and select products that match their risk tolerance. Past performance of the fund does not indicate future results. Caution is advised when investing in funds. Selling institutions (including the fund manager's direct sales agencies and other sales institutions) assess the risk of this fund based on relevant laws and regulations. Investors should promptly pay attention to the appropriateness opinions issued by the fund manager. The suitability opinions of various sales institutions may not necessarily be consistent, and the risk rating results of the fund product issued by fund sales institutions shall not be lower than the risk rating results provided by the fund manager. There may be differences in the fund's risk-return characteristics and risk等级 due to different consideration factors in the fund contract. Investors should understand the risk-return profile of the fund and make careful choices based on their investment objectives, time horizon, experience, and risk tolerance, bearing the risks themselves. The China Securities Regulatory Commission's registration of the above-mentioned funds does not indicate a substantive judgment or guarantee of their investment value, market prospects, or returns. Caution is advised when investing in funds.
A golden cross signal has formed in the MACD indicator, indicating favorable momentum for these stocks.